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Abstract 
The Wnt/β-catenin signalling pathway is pivotal for stem cell function and the control of cellular 
differentiation, both during embryonic development and tissue homeostasis in adults. Its activity is 
carefully controlled through the concerted interactions of concentration-limited pathway 
components and a wide range of posttranslational modifications, including phosphorylation, 
ubiquitylation, sumoylation, poly(ADP-ribosyl)ation (PARylation) and acetylation. Regulation of 
Wnt/β-catenin signalling by PARylation was discovered relatively recently. The poly(ADP-
ribose)polymerase (PARP) tankyrase PARylates AXIN1/2, an essential central scaffolding protein 
in the β-catenin destruction complex, and targets it for degradation, thereby fine-tuning the 
responsiveness of cells to the Wnt signal. The past few years have not only seen much progress in 
our understanding of the molecular mechanisms by which PARylation controls the pathway but also 
witnessed the successful development of tankyrase inhibitors as tool compounds and promising 
agents for the therapy of Wnt-dependent dysfunctions, including colorectal cancer. Recent work has 
hinted at more complex roles of tankyrase in Wnt/β-catenin signalling as well as challenges and 
opportunities in the development of tankyrase inhibitors. Here we review some of the latest 
advances in our understanding of tankyrase function in the pathway and efforts to modulate 
tankyrase activity to re-tune Wnt/b-catenin signalling in colorectal cancer cells. 
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AXIN, axis inhibition protein; b-TRCP, b-transducin repeats-containing protein; B9L, B-cell 
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CLL/lymphoma 9-like protein; CK1, casein kinase 1; CLEM, correlative light and electron 
microscopy; CRC, colorectal cancer; DAX, polymerising domain present in Dishevelled and AXIN; 
DKK1, Dickkopf-related protein 1; DVL, Dishevelled; EGFR, epidermal growth factor receptor; 
FoxM1, Forkhead box protein M1; FRAP, fluorescence recovery after photobleaching; GSK3, 
glycogen synthase kinase 3; IC50, inhibitory concentration of 50%; ISC, intestinal stem cell; JAK, 
Janus kinase; LEF1, lymphoid enhancer-binding factor 1; LRP5/6, low-density lipoprotein receptor-
related protein 5/6; MCR, mutation cluster region in APC; NAD+, nicotinamide adenine 
dinucleotide; NMR, nuclear magnetic resonance; PAR, poly(ADP-ribose); PARdU, PAR-dependent 
ubiquitylation; PARP, poly(ADP-ribose)polymerase; PDB, protein data bank; PI3K, 
phosphatidylinositol-3-kinase; RGS, regulator of G-protein signalling (domain); RING, really 
interesting new gene (domain); RNF, RING finger; SAM, sterile alpha motif (domain); SAR, 
structure-activity relationship; SBDD, structure-based drug design; STAT, signal transducer and 
activator of transcription; TBM, tankyrase-binding motif; TNKS/TNKS2, tankyrase; TNKSi, 
tankyrase inhibitor; TERF1/TRF1, telomeric repeat-binding factor 1; V5, epitope tag derived from 
the P and V proteins of paramyxovirus and simian virus 5, respectively; Wg/WNT, Wingless and its 
vertebrate orthologue; WWE, domain named after a motif containing two conserved Trp (W) 
residues and one conserved Glu (E)  
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Regulation of Wnt/b-catenin signalling by tankyrase-dependent AXIN poly(ADP-
ribosyl)ation – an overview 
The Wnt/β-catenin signalling pathway plays key roles during embryonic development, tissue 
homeostasis and regeneration (reviewed by Clevers and Nusse, 2012 and Clevers et al., 2014). 
Central to the pathway is the β-catenin destruction complex, which tightly controls the levels of 
nuclear, transcriptionally active β-catenin (reviewed by Stamos and Weis, 2013). Dysregulation of 
β-catenin destruction complex function underlies the vast majority of colorectal cancers (CRCs) and 
other conditions such as fibrosis, neurodegeneration and osteoporosis (reviewed by Clevers and 
Nusse, 2012 and Kahn, 2014). AXIN (AXIN1/AXIN2), the central scaffold of the destruction 
complex, directly binds all its core components: the scaffolding protein APC, the kinases GSK3 and 
CK1 and β-catenin (reviewed by Stamos and Weis, 2013) (Figure 1A). (AXIN1 and AXIN2 will be 
referred to collectively as AXIN where the discussed aspects apply to both.) The complex enables 
the phosphorylation of β-catenin at a phosphodegron to prime it for ubiquitylation and subsequent 
degradation by the proteasome (reviewed by Stamos and Weis, 2013). AXIN is thought to be the 
concentration-limiting component of the complex (Salic et al., 2000; Lee et al., 2003). Therefore, 
controlling its abundance is an effective way to regulate b-catenin destruction. Wnt/b-catenin 
signalling is regulated by a wide range of posttranslational modifications (reviewed by Gao et al., 
2014). The discovery of a regulatory role of tankyrase in Wnt/β-catenin signalling sparked much 
excitement given the limited number of known targetable enzymes in the pathway (Huang et al., 
2009). Tankyrase, with two human paralogues (TNKS and TNKS2; Tnks and Tnks2 in other 
species discussed; from here on simply referred to as “tankyrase” where concepts apply to both 
tankyrases), is a poly(ADP-ribose)polymerase (PARP), and as such catalyses the attachment of 
poly(ADP-ribose) (PAR) chains onto its substrates (reviewed by Gibson and Kraus, 2012 and 
Haikarainen et al., 2014a). In addition to its auto-PARylation activity, tankyrase binds and 
PARylates AXIN. In turn, PARylation activates the PAR-dependent E3 ubiquitin ligase 
RNF146/Iduna, which then ubiquitylates AXIN, tankyrase and itself, targeting the entire complex 
for proteasomal degradation (Callow et al., 2011; Zhang et al., 2011) (Figure 1A). This process, 
known as PAR-dependent ubiquitylation (PARdU) (DaRosa et al., 2015), is thought to occur 
constitutively and tune the receptiveness of cells to Wnt stimuli by limiting destruction complex 
formation (Wang et al., 2016b). A tankyrase-associated ubiquitin-specific protease (USP25) can de-
ubiquitylate tankyrase, thereby stabilising it and supporting PARdU of AXIN (Xu et al., 2017a). 
Recent studies point toward another role of tankyrase, namely in promoting the formation of active, 
membrane-localised Wnt signalosomes upon Wnt stimulation (Yang et al., 2016; Wang et al., 
2016a) (Figure 1B). Furthermore, additional tankyrase interactors in the Wnt/β-catenin pathway, 
other than AXIN, are emerging (Croy et al., 2016). Structure-function studies are providing a 
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detailed picture of the molecular mechanisms by which tankyrase controls Wnt/β-catenin signalling 
and are revealing non-catalytic scaffolding roles of tankyrase (Guettler et al., 2011; Morrone et al., 
2012; DaRosa et al., 2015; 2016; Eisemann et al., 2016; Mariotti et al., 2016; Riccio et al., 2016; 
Xu et al., 2017a). Conserved functions of tankyrase in the Wnt/β-catenin pathway are being 
increasingly appreciated from studies in Drosophila and human CRC cell lines (Lau et al., 2013; de 
la Roche et al., 2014; Yang et al., 2016; Wang et al., 2016b; 2016c). Recently developed tankyrase-
specific catalytic inhibitors are serving as tool compounds and promising pre-clinical leads for the 
treatment of CRC and other Wnt-dependent conditions (Lau et al., 2013; reviewed by Haikarainen 
et al., 2014a). Here, we discuss a selection of recent insights into the roles of tankyrase in the 
Wnt/β-catenin signalling pathway. In terms of potential therapeutic applications, we will focus on 
CRC, given its high incidence and the importance of the Wnt/b-catenin pathway in its emergence. 
 
Tankyrase as a scaffold in Wnt/β-catenin signalling – a structural perspective 
TNKS and TNKS2 share a highly similar multi-domain organisation: five N-terminal ankyrin 
repeat clusters (ARCs) for substrate binding are followed by a polymerising sterile alpha motif 
(SAM) domain and a C-terminal PARP catalytic domain (Figure 2A). With the exception of ARC3, 
the ARCs act as discrete substrate recognition domains for degenerate 8-amino-acid peptides of the 
consensus R-[any]-[any]-[small hydrophobic or G]-[D/E]-G-[no P]-[D/E], termed the tankyrase-
binding motif (TBM) (Seimiya, 2002; Seimiya et al., 2004; Guettler et al., 2011). (Briefly, an 
arginine at position 1 and glycine at position 6 of the TBM are essential. A small, hydrophobic 
residue or glycine are preferred at position 4, and acidic residues are optimal at positions 5 and 8, 
while proline is disallowed at position 7.) Crystal structures of human TNKS2 ARC4 with various 
TBM peptides (Guettler et al., 2011), of murine Tnks ARC2-3 in complex with Axin1 (Morrone et 
al., 2012), of human TNKS ARC1-3, combined with in-solution structural studies (Eisemann et al., 
2016), and of human TNKS ARC5 bound to the TBM of USP25 (Xu et al., 2017a), revealed the 
architecture of the ARCs and the principles of their substrate recognition. AXIN contains two 
TBMs in its N-terminus (Morrone et al., 2012), with the second motif bearing an unusual insertion 
(Figure 2B-E). The Tnks ARC2-3:Axin1 crystal structure shows a dimeric arrangement of ARC2-3 
with each TBM peptide bound to one copy of ARC2, respectively (Morrone et al., 2012). AXIN is 
also able to contact two ARCs in the same Tnks molecule (Eisemann et al., 2016). TNKS ARCs 1-3 
adopt a relatively rigid asymmetric U-shape, whereas ARCs 4-5 are more dynamic and flexibly 
linked to ARC1-3 (Eisemann et al., 2016). Multiple AXIN binding sites in the ARCs and two 
TBMs in AXIN enable their cooperative interaction, but distance and conformational restraints 
create a preference for bivalent AXIN to either simultaneously bind ARCs 1 and 2, 4 and 5 or 2 and 
5, with a preference for combinations involving ARC2, the strongest AXIN binder (Eisemann et al., 
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2016). When binding to ARCs 2 and 5, AXIN induces a more compact conformation of the ARCs, 
which might place the PARP domain into closer proximity to ARC-bound AXIN, in turn promoting 
AXIN PARylation (Eisemann et al., 2016). Further studies are needed to explore this hypothesis. In 
the context of polymeric tankyrase, it appears equally likely that AXIN binds separate tankyrase 
molecules in the same tankyrase filament, with different implications for tankyrase conformation 
and potentially a further augmentation of cooperativity (Mariotti et al., 2016; Riccio et al., 2016). 
Both TNKS and TNKS2 polymerise through their SAM domains (De Rycker and Price, 2004; 
Mariotti et al., 2016; Riccio et al., 2016). Recent crystallographic studies of the SAM domains 
revealed the electrostatic nature of the head-to-tail SAM-SAM interfaces within the helical filament 
(Mariotti et al., 2016; Riccio et al., 2016) (Figure 2F), in agreement with a polymer model guided 
by NMR studies to identify the residues perturbed upon polymerisation (DaRosa et al., 2016). 
Compatible with the outward-facing N- and C-termini in the filament (DaRosa et al., 2016; Mariotti 
et al., 2016; Riccio et al., 2016), full-length tankyrase indeed polymerises (De Rycker and Price, 
2004; Mariotti et al., 2016; Riccio et al., 2016). TNKS and TNKS2 form cytoplasmic puncta rather 
than microscopically visible filaments, which may reflect the dynamic nature of the polymers 
(Mariotti et al., 2016; Riccio et al., 2016). This is consistent with observations made for other 
proteins containing polymerising SAM domains (Isono et al., 2013) and for polymerising AXIN 
and DVL/DVL2 (Schwarz-Romond et al., 2007; Fiedler et al., 2011; reviewed by Bienz, 2014). 
Supporting this view, polymerisation-deficient TNKS and TNKS2 mutants localise diffusely 
(Mariotti et al., 2016; Riccio et al., 2016). Luciferase reporter assays revealed that scaffolding 
through the ARCs and SAM domain is essential for tankyrase function in Wnt/β-catenin signalling 
(Mariotti et al., 2016; Riccio et al., 2016). Surprisingly, tankyrase can drive Wnt/β-catenin activity 
even in the absence of its catalytic PARP activity, entirely through scaffolding (Mariotti et al., 
2016). Tankyrase polymerisation enables productive interactions with the limited pool of AXIN, 
through avidity effects arising from multivalency and polymerisation in both tankyrase and AXIN 
(Fiedler et al., 2011; Mariotti et al., 2016) (Figure 2G), a requirement that appears overridden by 
AXIN overexpression (Riccio et al., 2016 and our unpublished observations). The SAM domain 
and SAM-domain dependent polymerisation are also required for full tankyrase PARP activity (De 
Rycker and Price, 2004; Levaot et al., 2011; Mariotti et al., 2016; Riccio et al., 2016). Interestingly, 
while PARP activity is dispensable for tankyrase-driven Wnt/β-catenin signalling under basal 
conditions (Mariotti et al., 2016), it is necessary for tankyrase to potentiate Wnt-induced β-catenin 
activity (Riccio et al., 2016). This may well reflect the recently discovered requirement of AXIN 
PARylation in the formation of Wnt-induced signalosomes (see below) (Yang et al., 2016; Wang et 
al., 2016a) (Figure 1B). 
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A potential role of tankyrase in the formation of β-catenin degradasomes 
When AXIN is overexpressed or stabilised in APC-mutant cells by tankyrase inhibition (using the 
inhibitors JW67, JW74, JW55, XAV939, or G007-LK; see Table 1 and below for a discussion of 
inhibitors), it accumulates in cytoplasmic puncta, together with other β-catenin destruction complex 
components, including GSK3β, APC, β-catenin, b-TRCP and tankyrase (Waaler et al., 2011; 2012; 
de la Roche et al., 2014; Thorvaldsen et al., 2015; Martino-Echarri et al., 2016) (Figure 3). The 
puncta gradually disappear upon removal of the tankyrase inhibitor (TNKSi), and re-establish with 
subsequent inhibitor treatment (Thorvaldsen et al., 2015). The puncta, referred to as β-catenin 
degradasomes, are understood to be “morphological correlates” of β-catenin destruction complexes, 
which without tankyrase inhibition are not visible by light microscopy due to the normally low 
AXIN levels (de la Roche et al., 2014; Thorvaldsen et al., 2015; Pedersen et al., 2016). Several 
features illustrate functionality of these degradasomes. Firstly, they contain phosphorylated β-
catenin and also colocalise with ubiquitin and b-TRCP, a component of the E3 ubiquitin ligase 
responsible for β-catenin ubiquitylation (Thorvaldsen et al., 2015). Secondly, live-cell imaging by 
fluorescence recovery after photobleaching (FRAP) in SW480 cells showed that β-catenin is rapidly 
turned over in degradasomes (Thorvaldsen et al., 2015), demonstrating their capacity to degrade β-
catenin. 
Two recent studies suggest that tankyrase plays a structural role in degradasome formation 
(Thorvaldsen et al., 2015; Martino-Echarri et al., 2016). Correlative light and electron microscopy 
(CLEM) suggests that TNKS-GFP-containing degradasomes in TNKSi-treated SW480 cells 
correspond to electron-dense and possibly filamentous substructures (Thorvaldsen et al., 2015), 
perhaps reflecting the polymeric nature of both AXIN and tankyrase. Simultaneous silencing of 
both tankyrases abolishes degradasome formation (Martino-Echarri et al., 2016). Other studies have 
shown that, like tankyrase inhibition, TNKS/TNKS2 RNAi increases the levels of AXIN1/2 (Huang 
et al., 2009). Strikingly, despite increased AXIN levels, degradasomes are absent under 
TNKS/TNKS2-depleted conditions (Martino-Echarri et al., 2016), supporting a direct, structural 
role for tankyrase in degradasome formation. FRAP studies have shown that TNKS stably resides in 
degradasomes, similarly to AXIN (Schwarz-Romond et al., 2005; Thorvaldsen et al., 2015), 
although tankyrase and AXIN dynamics have not yet been studied in the same cell. The multivalent 
interactions of AXIN with tankyrase and the avidity-enhancing polymerisation of both proteins may 
underlie a scaffolding function of tankyrase in degradasome formation (Mariotti et al., 2016) 
(Figure 2G). Tankyrase polymerisation may be promoted by its catalytic inhibition (De Rycker and 
Price, 2004), which might offer a potential explanation for the TNKSi-induced stabilisation of 
degradasomes. APC2, which was recently reported to bind tankyrase (Croy et al., 2016), may also 
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contribute to the avidity-dependent degradasome assembly, given its numerous AXIN and β-catenin 
binding sites. 
AXIN2 protein levels rapidly increase upon tankyrase inhibition in SW480 cells, whereas AXIN1 
levels do not change until much later (Pedersen et al., 2016; Thorvaldsen et al., 2017). Knockdown 
of AXIN2 but not AXIN1 prevents degradasome formation (Thorvaldsen et al., 2017), indicating 
that AXIN2 is the predominant AXIN scaffold in these cells. The TNKSi-induced accumulation of 
AXIN2 is dependent on new protein synthesis (Thorvaldsen et al., 2017) and active transcription of 
the AXIN2 gene (Pedersen et al., 2016). Proteasome inhibition leads to increased levels of 
phosphorylated β-catenin in degradasomes (Thorvaldsen et al., 2015), but prolonged proteasome 
inhibition impairs degradasome formation (Martino-Echarri et al., 2016; Pedersen et al., 2016). 
Pedersen and colleagues proposed that the transcription factor FoxM1, whose activating 
phosphorylation is suppressed by proteasome inhibition, controls the AXIN2 gene (Pedersen et al., 
2016). AXIN2 is also a Wnt/β-catenin target gene as part of a negative feedback loop, and is highly 
expressed in APC mutated CRC cells (Yan et al., 2001; Jho et al., 2002; Lustig et al., 2002). It is 
unknown why tankyrase inhibitors induce β-catenin degradasomes in many CRC cells but far less 
so in cells with an intact Wnt/β-catenin pathway (de la Roche et al., 2014). It is possible that 
tankyrase inhibition strongly represses the AXIN2 gene in Wnt/β-catenin wild-type cells. 
Conversely, APC-mutant cells might still display residual AXIN2 transcription with ensuing AXIN2 
protein accumulation due to blocked PARdU and the formation of large degradasomes. 
Degradasome assembly depends on the concentrations of their components (Bienz, 2014), and it is 
likely that fully functional degradasomes also form in Wnt/β-catenin wild-type cells, but that these 
structures remain small. 
 
The structural basis of PARdU 
Once PARylated, AXIN is engaged by the PAR-binding E3 ubiquitin ligase RNF146/Iduna (Callow 
et al., 2011; Kang et al., 2011; Zhang et al., 2011). RNF146 consists of a RING domain, followed 
by a PAR-binding WWE domain and an extended C-terminus, which is predicted to be largely 
unstructured (Figure 4B). The PAR-dependency of the enzyme suggested an allosteric activation 
mechanism; in addition, PAR may serve as a scaffold to enable increased local concentrations of 
the enzyme (Callow et al., 2011; Kang et al., 2011; Zhang et al., 2011). A crystal structure of 
RNF146 (RING-WWE) bound to iso-ADP-ribose, an internal unit of PAR (Figure 4A), and an E2 
conjugating enzyme is compatible with the allosteric activation of RNF146 (DaRosa et al., 2015) 
(Figure 4C). Iso-ADP-ribose not only binds the WWE but also the RING domain (Wang et al., 
2012; DaRosa et al., 2015) and appears to induce restructuring of a loop which in the apo form of 
the RING domain extends into the E2-E3 enzyme contact region, thereby precluding the interaction 
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(Figure 4C). The restructured loop residues become part of an extended central helix in the RING 
domain, which no longer obstructs E2 binding (Figure 4C), a model supported by NMR 
spectroscopy and mutagenesis  (DaRosa et al., 2015). The extended C-terminus of RNF146 directly 
binds tankyrase via five proposed TBMs (DaRosa et al., 2015) (Figure 4B). It is noteworthy that all 
of these TBMs are atypical in their length or sequence, suggesting that they might be of relatively 
low individual affinity and may need to act collectively to recruit tankyrase. A model in which the 
tankyrase:RNF146 complex can still bind other TBM-containing proteins via the multivalent ARCs 
implies that tankyrase’s substrate specificity determines RNF146 substrate specificity (DaRosa et 
al., 2015). Like many PARPs, tankyrase modifies itself, and not all tankyrase binders are also 
PARylated (Bae, 2002; Guettler et al., 2011; Bisht et al., 2012). This raises the interesting 
possibility that non-PARylated tankyrase binders may still be ubiquitylated by RNF146 present in 
the complex, with RNF146 getting activated by tankyrase auto-PARylation or PAR attachment to 
different, simultaneously bound substrates. 
While tankyrase RNAi stabilises AXIN and reduces β-catenin-dependent transcription in certain 
CRC cell lines (Huang et al., 2009; Callow et al., 2011), silencing of RNF146 fails to increase 
AXIN levels in HCT-15 or SW480 CRC cells, both of which bear APC truncations, and does not 
inhibit Wnt/β-catenin signalling in HCT-15 cells (Callow et al., 2011). This suggests that there are 
alternative pathways for the degradation of PARylated AXIN in these cells (Callow et al., 2011). 
The existence of numerous RING-type E3 ubiquitin ligases with PAR-binding WWE domains 
suggests that functional redundancies may exist (Wang et al., 2012). 
 
Tankyrase and APC set a threshold for Wnt responsiveness by limiting AXIN abundance 
To assess the maximum AXIN level still allowing productive Wnt/b-catenin signalling, Wang et al. 
engineered flies overexpressing C-terminally V5 epitope-tagged Axin (Axin-V5) (Wang et al., 
2016b). (Note that Drosophila has a single Axin paralogue; see Figure 2C.) Despite an up to four-
fold Axin-V5 overexpression, flies develop normally with only a mild defect attributable to 
inhibited Wg signalling (Wang et al., 2016b), in agreement with previous studies (Peterson-Nedry 
et al., 2008). This suggested that Axin-V5 is still subject to physiological regulation at this level. 
Likewise, loss of tankyrase (of which there is also only a single paralogue in Drosophila) results in 
a mild (two- to three-fold) increase in endogenous Axin abundance in larvae, without measurable 
developmental impact (Feng et al., 2014; Wang et al., 2016b; 2016c). However, developmental 
defects and loss of Wg/Armadillo target gene expression are observed when Axin-V5 is expressed 
in wing imaginal discs in a tankyrase null background, which results in a further three-fold increase 
of Axin-V5 levels, positioning the inhibitory threshold for Axin three- to nine-fold above 
endogenous regulated levels (Wang et al., 2016b). This illustrates tankyrase’s strong capacity to 
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buffer negative regulation of Wg signalling by Axin, a phenomenon also seen in mammalian cells 
(Mariotti et al., 2016). These observations are compatible with the previous finding that knockdown 
of tankyrase in the developing wing only leads to a Wg phenotype if Axin is simultaneously 
overexpressed (Feng et al., 2014). 
Besides their role in promoting β-catenin/Armadillo degradation, Apc/Apc2 also play a positive 
role in regulating Wg/Armadillo signalling by posttranscriptionally limiting Axin levels (Takacs et 
al., 2008; Wang et al., 2016b). Accordingly, Axin-V5 accumulates in imaginal discs lacking Apc1 
and Apc2 (Wang et al., 2016b). The regulation of Axin levels by Apc is strictly dependent on the 
Apc-binding RGS domain of Axin, suggesting that a physical interaction between the two proteins 
is required (Wang et al., 2016b). Surprisingly, while the ability of tankyrase to destabilise Axin is 
independent of Apc, the TBM of Axin is necessary for Axin destabilisation by Apc, suggesting that 
tankyrase binding is required (Wang et al., 2016b). Alternatively, the Axin N-terminus may play a 
tankyrase-independent role in Axin regulation by Apc. The mechanism by which Apc destabilises 
Axin remains unclear, and it will be interesting to decipher whether PARdU is involved. A recent 
report suggests the existence of a TBM in Apc2 (Croy et al., 2016). Tankyrase may bind to both 
Apc2 and Axin, thereby providing an additional scaffolding role. The existence of partially 
separable degradation pathways for Axin, through tankyrase and Apc/Apc2, may explain the mild 
Tnks null phenotype in flies (Wang et al., 2016b). By analogy, Wang et al. propose that if AXIN 
regulation by APC is lost in APC-mutant CRC cells, then these cells might be particularly 
susceptible to tankyrase inhibition, in contrast to APC wild-type cells, opening the possibility for 
selectively targeting APC-mutant cells (Wang et al., 2016b). This is an interesting idea for further 
exploration. 
 
Tankyrase mouse models 
The physiological role of tankyrase in Wnt/b-catenin signalling is still far from being fully 
understood. In mice, loss of both tankyrases gives rise to embryonic lethality, without indication 
that lethality is attributable to defective Wnt/b-catenin signalling (Chiang et al., 2008). Individual 
knockout of either Tnks or Tnks2 results in non-pathogenic phenotypes, but again there is no sign 
of a dysregulated Wnt pathway (Chiang et al., 2006; Hsiao et al., 2006; Chiang et al., 2008). One 
may speculate that embryonic lethality in the double knockout arises from another essential role of 
tankyrase in development or pleiotropy due to the complex involvement of tankyrase in many 
biological processes, masking a function in Wnt/b-catenin signalling. Moreover, these observations 
point toward a substantial functional redundancy between the two tankyrases. In the absence of 
conditional Tnks/Tnks2 knockout mice, the role of tankyrase in Wnt-dependent physiology is 
difficult to assess. However, an Axin2 V26D mutation, which maps to the stronger, N-terminal 
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TBM of murine Axin2 (Figure 2C), also results in embryonic lethality, but with an identifiable Wnt 
phenotype (Qian et al., 2011). The mutation is expected to abrogate tankyrase binding (Guettler et 
al., 2011), compatible with increased Axin2 levels and reduced Wnt/b-catenin signalling in most 
tissues (Qian et al., 2011). However, increased rather than decreased Wnt/b-catenin signalling is 
observed in the late primitive streak, a structure that marks the beginning of gastrulation and the 
definition of body axes, and consequential formation of ectopic tails (Qian et al., 2011), an 
observation that points to complex functions of the tankyrase-Axin interaction. The Axin2 mutation 
exposes a physiological role of tankyrase in Wnt/b-catenin signalling that was likely masked in the 
Tnks/Tnks2 double-knockout mice. 
 
Tankyrase controls adult intestinal stem cell homeostasis in Drosophila 
A more detailed analysis of Tnks mutant flies revealed a sharp drop in viability upon nutrient 
limitation, paralleled by an accumulation of Axin and hyperproliferation of intestinal stem cells 
(ISCs) in the midgut (Wang et al., 2016c). The Drosophila midgut can be subdivided into several 
morphologically and physiologically distinct domains. It displays high levels of Wg target gene 
transcription close to the inter-domain boundaries, which may represent source areas for the Wg 
ligand (Buchon et al., 2013; Tian et al., 2016). Loss of tankyrase distant from the midgut-hindgut 
boundary, where β-catenin/Armadillo activity is low, completely abolishes the activation of Wg 
reporters in this region (Wang et al., 2016c). This is not the case in areas close to the midgut-
hindgut boundary, where Wg signalling is high. The authors suggested that by counteracting Axin, 
tankyrase amplifies β-catenin/Armadillo activity in compartments of otherwise low pathway 
activity. They hypothesized that tankyrase’s context-specific roles may explain seemingly 
contradicting in-vivo functions of tankyrase in flies and zebrafish (Huang et al., 2009; Feng et al., 
2014) and that similar mechanisms may be in place where Wnt gradients are observed in 
vertebrates, for example in the gut (Wang et al., 2016c). (See below for a further discussion of 
tankyrase’s roles in the gastrointestinal tract.) Interestingly, hyperproliferation of ISCs is non-cell-
autonomous: it does not result from tankyrase loss or abrogated Wg/Armadillo signalling in ISCs 
but in enterocytes (Tian et al., 2016; Wang et al., 2016c). The authors suggested that decreased Wg 
signalling in enterocytes upon loss of tankyrase promotes JAK/STAT signalling in ISCs, which in 
turn drives their proliferation during homeostasis. 
 
A role of AXIN PARylation in Wnt signalosome assembly 
While tankyrase’s role in PARdU of AXIN is well established, two recent studies point to a novel 
function in Wnt signalosome assembly (Yang et al., 2016; Wang et al., 2016a) (Figure 1B). During 
Drosophila embryonic development, the abundance of weakly expressed Axin-V5 changes in a 
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biphasic manner (Yang et al., 2016). Initially distributed uniformly in the ectoderm, Axin-V5 first 
accumulates in segmental stripes marked by Wg induction. Secondly, with progressing 
development, Axin levels drop specifically in the Wg stripes, an observation analogous to delayed 
AXIN destabilisation in mammalian cells (Li et al., 2012 and references therein). In embryos 
expressing an Axin-V5 mutant variant lacking the TBM, or in embryos lacking tankyrase, Axin-V5 
levels are uniformly high. Early Axin-V5 stripes fail to form, with a concomitant loss of normal Wg 
target gene expression. Importantly, this is not merely due to increased Axin-V5 levels under these 
circumstances since strong Axin-V5 overexpression does not copy this phenotype (Yang et al., 
2016). The authors hence propose a role of tankyrase in regulating Axin function rather than levels 
(Figure 1B). Studies in Drosophila and work with Drosophila cells and HEK293T cells showed 
that Wg/Wnt stimulation results in accumulation of PARylated Axin-V5/AXIN1 with an enhanced 
formation of AXIN- and LRP6/Arrow-containing Wnt/Wg signalosomes (Yang et al., 2016). 
Capitalising on the ability to detect endogenous Drosophila Axin, a second study suggests that 
Axin is present in both the cytoplasm and at the membrane, even under basal conditions. Wg 
stimulation results in Axin accumulation in both compartments, with an enrichment of PARylated 
Axin at the membrane (Wang et al., 2016a). Forcing Axin to the membrane under basal conditions 
increases its PARylation and destabilisation, presumably by PARdU, suggesting that tankyrase acts 
at the membrane or Axin’s susceptibility to PARylation is augmented upon membrane recruitment 
(Wang et al., 2016a). Phosphorylation by GSK3 (Kim et al., 2013) or binding of the small molecule 
HLY78 (Wang et al., 2013) was reported to induce an open AXIN conformation for productive 
interaction with LRP6. AXIN PARylation may control the assembly of the Wnt signalosome 
complex in a similar manner. Alternatively, PAR itself may act as a molecular glue to recruit AXIN 
to Wnt signalosomes. While the intact LRP5 C-terminus is required for AXIN binding (Mao et al., 
2001), it is presently not clear whether AXIN and LRP5/6 interact directly (Mao et al., 2001; Kim 
et al., 2013; Wang et al., 2013), but there are indications that this may be the case (MacDonald et 
al., 2011). Future studies will unravel the mechanisms behind the Wnt/Wg-induced accumulation of 
PARylated Axin and the role of PARylation in signalosome assembly. Yang et al. propose that the 
PAR-assisted signalosome formation enables a rapid response to Wnt signals while the subsequent 
downregulation of AXIN limits the re-assembly of b-catenin destruction complexes, thereby 
conferring both responsiveness and robustness to the pathway (Yang et al., 2016). 
 
Tankyrase inhibitors 
In this section, we provide an overview of tankyrase inhibitors; for more comprehensive 
discussions, we refer the reader to other recent reviews (Lehtiö et al., 2013; Steffen et al., 2013; 
Haikarainen et al., 2014a). All small-molecule tankyrase inhibitors developed to date are mimetics 
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of b-NAD+ or its adenosine or nicotinamide portions. The first potent toolbox tankyrase inhibitors, 
XAV939 (Huang et al., 2009), IWR-1 and IWR-2 (Chen et al., 2009; Gunaydin et al., 2012), were 
discovered in phenotypic screens designed to identify antagonists of the Wnt/β-catenin pathway, as 
were the inhibitors JW74 (Waaler et al., 2011), JW55 (Waaler et al., 2012), WIKI4 (James et al., 
2012) and K-756 (Okada-Iwasaki et al., 2016). Numerous additional inhibitors were established 
through diverse approaches (Zhan et al., 2014), including screening for compounds that rescue 
tankyrase-induced lethality of yeast cells (Yashiroda et al., 2010) or induce a mitotic spindle defect 
(Johannes et al., 2015b), fragment screening (Larsson et al., 2013; de Vicente et al., 2015), 
proteomics (Thomson et al., 2017), in-silico screening or substructure searching, followed by 
compound optimisation (Bregman et al., 2013b; Elliott et al., 2015), screening of a DNA-encoded 
library (Samain et al., 2015), and extensive structure-activity relationship (SAR) studies, assisted by 
the structural analysis of tankyrase/PARP:inhibitor complexes (Hua et al., 2013; Shultz et al., 2013; 
Voronkov et al., 2013; Narwal et al., 2013a; Liscio et al., 2014; Qiu et al., 2014; Haikarainen et al., 
2014b; Kumpan et al., 2015; Nkizinkiko et al., 2015; Paine et al., 2015; Haikarainen et al., 2016; 
Thomson et al., 2017). Numerous more drug-like molecules, with optimised pharmacological 
properties, are now available, for example G007-LK (Lau et al., 2013; Voronkov et al., 2013) and 
NVP-TNKS656 (Shultz et al., 2013). Table 1 gives examples of published tankyrase inhibitors.  
 
Inhibitor binding sites on the tankyrase PARP domain  
The tankyrase PARP domain shares strong homology with the catalytic domains of the 17 human 
Diphtheria-toxin-like ADP-ribosyltransferases (ARTDs) (reviewed by Hottiger et al., 2010). 
Among all ARTDs known to synthesise PAR (Vyas et al., 2014), the TNKS/TNKS2 PARP 
domains are unique in that they coordinate zinc, lack an N-terminal helical regulatory subdomain 
and also lack a loop distal to the active site (Lehtiö et al., 2008). In all other respects, they share the 
typical structural elements with other ARTD catalytic domains (Figure 5A). A so-called donor site 
coordinates the co-substrate NAD+ while the acceptor site accommodates either the peptide for the 
priming modification or the growing PAR chain poised for extension (Figure 5A). The donor site is 
lined by three loops: the donor site or D-loop, a glycine-rich G-loop and a phenylalanine-containing 
F-loop (Figure 5A). Tankyrase contains a catalytic H-Y-E triad required for PAR synthesis (Figure 
5A). All tankyrase inhibitors developed to date target the NAD+-binding donor site, but can broadly 
be classified by three binding modes, according to our structural understanding of NAD+ binding to 
Diphtheria toxin (Bell and Eisenberg, 1996). Inhibitors either primarily engage the nicotinamide 
subsite (e.g., XAV939) (Karlberg et al., 2010) the adenosine subsite (e.g., IWR-1 and G007-LK) 
(Narwal et al., 2012; Voronkov et al., 2013) or both sites in the case of the more recently developed 
dual-site inhibitors (Bregman et al., 2013b) (Figure 5A; Table 1). In some instances, a phosphate 
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site between the two subsites is specified as well (reviewed by Steffen et al., 2013). Crystal 
structures of tankyrase catalytic domains without inhibitor show closed D-loop conformations, 
albeit different ones in apo-TNKS and apo-TNKS2 with indications of flexibility (Lehtiö et al., 
2008; Karlberg et al., 2010). Adenosine site binders appear to induce their own pocket, conferring 
disorder or conformational changes to the D-loop (Lehtiö et al., 2008; Gunaydin et al., 2012; Shultz 
et al., 2012). Hence, the adenosine subsite appears highly adaptable and is sometimes referred to as 
the “induced pocket”. 
 
Achieving selectivity 
PARP inhibitor profiling against ARTDs revealed a remarkable promiscuity for a number of PARP 
inhibitors (Wahlberg et al., 2012; Thorsell et al., 2017). For example, XAV939 inhibits TNKS, 
TNKS2, PARP1 and PARP2 with comparable potency (e.g., IC50 values of 95, 5, 74, 27 nM in a 
direct comparison using the catalytic domains of TNKS and TNKS2 and full-length PARP1 and 2, 
respectively), while IWR-1 is more specific for the tankyrases (no measurable IC50 for full-length 
PARPs 1 and 2) (Thorsell et al., 2017). High-resolution PARP domain:TNKSi co-crystal structures 
have (1) rationalised TNKSi selectivity and (2) enabled structure-based drug design of more 
selective and potent tankyrase binders (reviewed by Lehtiö et al., 2013; Steffen et al., 2013; 
Haikarainen et al., 2014a). Specific examples for the former include G007-LK, which was 
optimised from JW74 (Lau et al., 2013; Voronkov et al., 2013), and WIKI4 (James et al., 2012; 
Haikarainen et al., 2013). Examples for the latter include NVP-TNKS656, developed from 
XAV939 (Shultz et al., 2013), and dual-site inhibitors (Hua et al., 2013) (Table 1). These studies 
demonstrated that the unique structural features of the tankyrase catalytic domain can be exploited 
to gain selectivity. For example, WIKI4 in the adenosine subsite would sterically clash with the 
helical subdomain in PARPs 1-3 (Haikarainen et al., 2013). More subtle differences can also be 
harnessed. Compared to other PARPs, the D-loop of tankyrases is 3 amino acids shorter, more 
flexible and often disordered in crystal structures of the domain with inhibitors, due to the absence 
of three proline residues, and characterised by large hydrophobic amino acids, which confer a 
narrower, more hydrophobic donor site pocket (Lehtiö et al., 2008; Wahlberg et al., 2012). 
Selectivity and potency can be gained by “growing” compounds toward this narrow pocket, as seen 
in the optimisation of quinazolinones (Nathubhai et al., 2013), tetrahydro-1,6-naphtyridin-5-ones 
(Kumpan et al., 2015) and the XAV939 core to NVP-TNKS656 (Shultz et al., 2013) (Table 1).	 Of 
note, although selectivity over other ARTDs can be achieved, many other enzymes also use NAD+ 
as a co-substrate, and so inhibitors designed to target the NAD+ donor site may have unknown off-
target effects at high concentrations. However, the example of sirtuins shows that this potential 
challenge can be overcome (Ekblad and Schüler, 2016). 
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Future developments 
While further optimisation of catalytic tankyrase inhibitors is progressing, non-catalytic scaffolding 
roles of tankyrase in Wnt/β-catenin signalling are emerging (Mariotti et al., 2016), and these may be 
augmented when prolonged TNKSi treatment results in tankyrase stabilisation by blocked PARdU 
(Huang et al., 2009). Furthermore, overexpression of tankyrase in several tumour types has been 
reported (Matsutani et al., 2001; Gelmini et al., 2004; 2006; 2007; Shervington et al., 2007; 
Shebzukhov et al., 2008; Zhao et al., 2009; Gao et al., 2011; Tang et al., 2012; Busch et al., 2013) 
and may accentuate tankyrase’s concentration-dependent scaffolding functions, contributing to 
TNKSi resistance (Mariotti et al., 2016). Therefore, blocking tankyrase’s ARC- and SAM-
dependent scaffolding functions holds considerable potential. Importantly, the ARCs and SAM 
domain are highly conserved between the two tankyrases (Figure 2A) but unique among the ARTD 
family, therefore offering the opportunity for target selectivity of potential compounds over other 
ARTDs, in addition to the potential benefits of inhibiting non-catalytic scaffolding functions. 
Moreover, potential interference with other NAD+-dependent enzymes could be circumvented by 
this approach. Whereas blocking SAM-domain-dependent polymerisation appears challenging due 
to the relatively shallow polymerisation interface, targeting the deeper TBM-binding pocket on the 
ARCs is more promising (Guettler et al., 2011; Morrone et al., 2012). This binding pocket is not 
conserved across ankyrin repeat proteins in general and appears to be unique to tankyrase. Given 
the presence of four substrate-binding ARCs, abrogation of each of these substrate/ligand binding 
sites would likely be required, in both TNKS and TNKS2. However, this appears feasible given the 
conservation of the TBM-binding pocket across the TNKS and TNKS2 ARCs (Guettler et al., 
2011). Xu et al. have recently shown that a stapled TBM peptide, based on a previously reported 
optimised TBM sequence (Guettler et al., 2011) and fused to a cell-permeability conferring peptide, 
can compete with AXIN and abrogate Wnt signalling (Xu et al., 2017b) (Figure 5B). This proof-of-
concept study will encourage further development of tankyrase substrate binding antagonists. While 
a recent tankyrase interactome study is in agreement with the notion that TNKS and TNKS2 are 
largely functionally redundant (Li et al., 2017), there may be benefit to selectively targeting either 
TNKS or TNKS2, should unique functions emerge in the future, which may be TNKS/TNKS2-
intrinsic or result from other sources such as differential expression or regulation. One inhibitor 
study (see Table 1, compound 3) suggests that, in principle, a certain degree of such selectivity can 
be achieved (Larsson et al., 2013). 
 
Functional and pre-clinical studies of tankyrase inhibitors in CRC 
Differential sensitivity of CRC cell lines to tankyrase inhibition 
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Most CRC tumours (≈ 80%) are hemizygous for C-terminal truncations of APC (reviewed by 
Bodmer, 2006), focussed at a hotspot area known as the mutation cluster region (MCR) (Miyoshi et 
al., 1992; Kohler et al., 2008; reviewed by Minde et al., 2011) (Figure 6A). Following the N-
terminal Armadillo repeat domain, APC contains three 15-amino-acid β-catenin-binding repeats, 
seven 20-amino-acid β-catenin-binding repeats and three interspersed AXIN-binding SAMP 
repeats, among other elements not required for APC’s function in Wnt/b-catenin signalling 
(reviewed by Stamos and Weis, 2013). Dependent on the position of the truncating mutation, a 
variable number of these motifs is lost (Figure 6A). In APC-truncated CRC cells, an inability to 
assemble a functional β-catenin destruction complex underlies the accumulation of transcriptionally 
active β-catenin. A range of studies has investigated the responsiveness of model CRC cell lines to 
tankyrase inhibition (Lau et al., 2013; de la Roche et al., 2014; Tanaka et al., 2017). While it would 
have been conceivable that the assembly and function of the b-catenin destruction complex cannot 
be sufficiently rescued by tankyrase inhibition in the absence of fully functional APC, there clearly 
are cases in which dysregulated Wnt/b-catenin signalling can be curbed. In SW403 and COLO-
320DM cells, both of which bear extensive C-terminal APC truncations (Figure 6A), tankyrase 
inhibition (by G007-LK, IWR-1 or XAV939) gives rise to AXIN2 stabilisation, the formation of β-
catenin degradasomes (in COLO-320DM cells), a robust reduction in active (non-phosphorylated) 
β-catenin and prominently attenuated β-catenin-dependent transcription, both in reporter assays and 
at the level of endogenous Wnt/b-catenin target genes (Lau et al., 2013; de la Roche et al., 2014; 
Tanaka et al., 2017). Importantly, tankyrase inhibition limits the proliferation of these cells in cell 
culture (for G007-LK and IWR-1) and xenograft (for G007-LK) models (Lau et al., 2013; Tanaka et 
al., 2017). A similar cell response to tankyrase inhibition is observed in DLD-1 and HCT-15 cells, 
although the levels of active b-catenin are reduced less robustly and the transcriptional effect is 
more subtle (Lau et al., 2013; de la Roche et al., 2014; Tanaka et al., 2017). Conversely, in SW480 
and SW620 cells, although tankyrase inhibition results in the stabilisation of AXIN2, degradasome 
formation and a strong decrease in active β-catenin levels, it fails to block Wnt/β-catenin target 
genes or the TOPFlash reporter (Lau et al., 2013; de la Roche et al., 2014). In yet another group of 
CRC cells (COLO-205, HT-29, HCC2998 and LS-411N), tankyrase inhibition increases AXIN1/2 
levels but with only a modest or no decrease in active β-catenin levels (Lau et al., 2013; Tanaka et 
al., 2017). For KM12 cells, no effect on the levels of AXIN1/2 or active β-catenin levels and b-
catenin-dependent transcription was observed upon tankyrase inhibition (Tanaka et al., 2017). As 
expected, Wnt/b-catenin signalling in CRC cells with oncogenic mutations in β-catenin (LS174T, 
HCT116) or β-catenin-independent CRC cells (RKO) are not sensitive to tankyrase inhibition (Lau 
et al., 2013; Tanaka et al., 2017). 
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Tankyrase inhibition can therefore restore, at least partially, b-catenin destruction complex function 
in a subset of APC-mutant CRC cells (Figure 6A). Why another subset of CRC cell lines is TNKSi-
resistant is being investigated. It has been proposed that high levels of β-catenin in SW480 cells 
account for TNKSi resistance (Lau et al., 2013), but β-catenin levels in the TNKSi-sensitive 
COLO-320DM cells appear comparable (de la Roche et al., 2014). Compared to SW480, COLO-
320DM cells appear to have higher levels of AXIN1, TNKS and phospho-β-catenin after tankyrase 
inhibition (de la Roche et al., 2014), suggesting that β-catenin may be sequestered in stalled 
destruction complexes, thereby limiting the availability of active β-catenin. 
A potential correlation between the site of APC truncation and tankyrase inhibitor sensitivity has 
been explored, both in CRC cell lines and tumour-derived cells from patients (Tanaka et al., 2017). 
APC truncations removing all β-catenin-binding 20-amino-acid repeats (as in COLO-320DM and 
SW403 cells; Figure 6A) were proposed to render cells TNKSi-responsive at the level of cell 
proliferation and might serve as a predictive biomarker (Tanaka et al., 2017). Another 
distinguishing feature of these cells is their particularly strong Wnt/β-catenin pathway activity 
(Tanaka et al., 2017). The authors suggest that the longer APC variants of other cell lines act as 
hypomorphs maintaining a higher residual level of β-catenin regulation: their silencing further 
stabilises β-catenin. Tankyrase inhibitors (G007-LK, IWR-1) can revert this accumulation, but not 
reduce β-catenin abundance below its cell-characteristic elevated levels (Tanaka et al., 2017). In 
turn, cell proliferation remains unresponsive to tankyrase inhibition (Tanaka et al., 2017). The 
genetic background of additional cell lines and tumour samples will need to be explored to confirm 
the suitability of APC truncations as predictive biomarkers for TNKSi sensitivity. In line with a 
requirement of AXIN2 for degradasome formation (see above), tankyrase inhibitors depend on 
AXIN2 to reduce active β-catenin levels (Tanaka et al., 2017). Large APC truncations, eliciting 
high β-catenin activity and thus AXIN2 gene transcription, may be required for the TNKSi-induced 
accumulation of sufficient amounts of AXIN2. Indeed, absolute AXIN2 mRNA levels are high in 
COLO-320DM cells, and upon tankyrase inhibition remain higher than in many other CRC cell 
lines (Tanaka et al., 2017). 
Upon prolonged Wnt stimulation, sequestration of β-catenin in nuclear transcriptional complexes 
may shield β-catenin from the β-catenin destruction complex and account for TNKSi (XAV939) 
resistance (de la Roche et al., 2014). High expression levels of LEF1 and B9L and a CRC 
environment providing sustained Wnt levels are potential predictors of tankyrase inhibitor 
resistance (de la Roche et al., 2014). Moreover, the acquisition of APC mutations is considered an 
early event in the emergence of CRC, and secondary mutations in genes such as KRAS, P53 and 
SMAD4 contribute to driving carcinogenesis (Drost et al., 2015); such mutations may modulate the 
TNKSi response, although this remains speculative. Of note, DLD-1 colony formation can be 
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inhibited with XAV939 under low- but not high-serum conditions (Huang et al., 2009; Bao et al., 
2012; Lau et al., 2013), and similarly DLD-1 and HCT-15 colony formation does not respond to 
G007-LK at high serum, while that of COLO-320DM and SW403 cells does (Lau et al., 2013). This 
points to additional sensitivity determinants outside the APC and b-catenin mutational landscape, 
although simple compound sequestration by serum components may in some cases also contribute. 
In support of a more complex determination of sensitivity, Mashima et al. generated a TNKSi-
resistant COLO-320DM line, showing decreased Wnt/b-catenin signalling and upregulated mTOR 
signalling (Mashima et al., 2017). These cells were generated to tolerate IWR-1 but also displayed 
considerable resistance to G007-LK. The authors showed that the mTOR pathway determines 
TNKSi resistance in these cells. In conclusion, we need to better understand how the genetic and 
signalling profile of CRC cells and tumours affects TNKSi responsiveness. Furthermore, a much 
deeper analysis of the β-catenin destruction complex and the Wnt signalosome is required to 
appreciate the mechanisms by which tankyrase inhibition affects the molecular events underlying 
Wnt/b-catenin signalling, both in the context of wild-type and mutant APC. 
 
Tankyrase inhibitors in murine models 
In-vivo preclinical studies have demonstrated the anti-tumour activity of various tankyrase 
inhibitors (Waaler et al., 2011; 2012; Lau et al., 2013). JW74 was studied in both xenograft and the 
ApcMin mouse models and reported to be well tolerated while reducing both the total tumour load in 
the small intestine and the tumour number in the colon (Waaler et al., 2011). Similar observations 
were made for JW55 in mice with a conditional Apc truncation in the ISC compartment (Waaler et 
al., 2012). An improved derivative of JW74, G007-LK, which inhibits tankyrase with double-digit 
nanomolar IC50 values and good specificity (Table 1) (Voronkov et al., 2013), decreases the tumour 
area in the small intestine of these mice by approximately two thirds and shows significant 
inhibition of tumour growth in various xenograft models with APC-mutant human cell lines 
(SW480, COLO-320DM and SW403) (Lau et al., 2013). 
Intestinal toxicity remains a major challenge for many Wnt/b-catenin pathway inhibitors (reviewed 
by Kahn, 2014). A more careful analysis of the effects of G007-LK at dose-limiting levels revealed 
reduced cell proliferation in crypt bases of the small intestine, inflammation, necrosis, disrupted 
epithelial architecture, with ensuing weight loss and morbidity (Lau et al., 2013). Whether the 
observed toxicity is reversible has not been explored. Conversely, in a study investigating the role 
of tankyrase in glucose metabolism, the long-term (six-month) treatment of mice with G007-LK at 
a lower dose did not result in detectable toxicity despite the observed stabilisation of Axin1 (Zhong 
et al., 2016a). Since the expression of the Wnt pathway antagonist Dkk1 (Dickkopf-related protein 
1) in the gut epithelium gives rise to similar toxicity (Pinto et al., 2003; Kuhnert et al., 2004; Lau et 
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al., 2013), it is likely that TNKSi toxicity is an on-target, Wnt/β-catenin pathway-specific effect. A 
mouse xenograft study evaluating the tankyrase inhibitor G-631 (patent by Feng et al., 2013) also 
revealed considerable intestinal toxicity, even at sub-therapeutic doses (Zhong et al., 2016b). 
Importantly, ablation of Wnt signalling by either adenoviral Dkk1 expression or treatment with G-
631 is reversible (Kuhnert et al., 2004; Zhong et al., 2016b). 
While toxicity poses challenges in continued efforts to explore the therapeutic potential of tankyrase 
inhibitors, it is no reason to be discouraged. Does TNKSi toxicity indeed reflect on-target or off-
target action of the inhibitors? What is the tissue distribution of the compounds? For example, do 
they accumulate in the gastrointestinal tract, aggravating toxicity? Do chemically distinct tankyrase 
inhibitors display similar signs of toxicity? The fact that SW480 cell xenograft growth can be 
contained by tankyrase inhibition despite the incomplete penetrance on β-catenin dependent 
transcription (see above) suggests that full inhibition of signalling might not be required for a 
therapeutic effect; so what degree of β-catenin inhibition translates into a biological effect? 
Moreover, different dosage and timing regimes could be implemented to manage known toxicities 
(reviewed by Meric-Bernstam and Mills, 2012). Encouragingly, inhibitors of the acyl transferase 
Porcupine, which palimitoylates Wnt during its biogenesis, show limited intestinal toxicity at 
effective doses, suggesting that substantial therapeutic windows can be achieved by targeting the 
Wnt/b-catenin pathway (Liu et al., 2013; Proffitt et al., 2013; reviewed by Madan and Virshup, 
2015). The point of intervention in the pathway, drug specificity and potency, pharmacokinetics, 
functional redundancy of targeted pathway components and the genetic background of the tumour 
cells may all define the therapeutic window. Combination with inhibitors targeting additional 
cancer dependencies (e.g., EGFR and PI3K-AKT) provides another possible strategy for increasing 
the effectiveness of tankyrase inhibitors while ensuring their safety (Casas-Selves et al., 2012; 
Tenbaum et al., 2012; Arques et al., 2016). 
A deeper knowledge of the responses and toxicities elicited by Wnt/b-catenin pathway modulators 
in different species is much needed to exploit b-catenin dependencies in cancer. With the vast range 
of known and putative tankyrase targets (Guettler et al., 2011; Li et al., 2017), it would be 
surprising if TNKSi effects and toxicities were entirely due to Wnt/b-catenin pathway inhibition. 
Another prominent system highly relevant to the human stem cell compartment is telomere length 
homeostasis, which is also regulated by tankyrase, as is sister telomere resolution in mitosis (Smith 
et al., 1998; Smith and de Lange, 2000; Canudas et al., 2007; Kulak et al., 2015). Telomeric 
functions require tankyrase to bind TRF1/TERF1 (telomeric repeat-binding factor 1). Importantly, 
telomere regulation by tankyrase is not conserved in mice since murine Trf1/Terf1 lacks the TBM 
(Figure 6B) and does not bind tankyrase (Muramatsu et al., 2007; reviewed by Hsiao and Smith, 
2008). Consistent with an absent role of telomeric tankyrase functions in mice, Tnks and Tnks2 
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knockout mice do not display any telomere phenotype (Hsiao et al., 2006; Chiang et al., 2008), but 
a definitive answer will be obtained from comparing murine and human cells deficient in both 
tankyrases. Therefore, pre-clinical studies of tankyrase inhibitors in mice and other species lacking 
the Terf1 TBM (e.g., zebrafish, Figure 6B) are unlikely to predict the full extent of biological 
effects and toxicity in humans. Conversely, rabbits or Chinese hamsters, for example, both display a 
functional TBM in Terf1 and might be more suitable models for studying the in-vivo consequences 
of tankyrase inhibition, at least with regards to Wnt/b-catenin signalling and telomere maintenance. 
In rats, the somewhat stronger deviation of the TBM will require a prior validation of a telomeric 
role for tankyrase (Muramatsu et al., 2007). Telomere maintenance in Drosophila occurs via a 
transposon-mediated mechanism rather than telomerase (Villasante et al., 2008), and a telomeric 
tankyrase link in flies is therefore unlikely. While Wg/Armadillo pathway regulation by tankyrase 
is clearly evident in Drosophila, some mechanistic aspects may be different, for example given that 
Drosophila Axin only bears a single TBM (Figure 2C). 
 
 
Outstanding Questions 
The past few years have seen a rapid progress in our understanding of how Wnt/b-catenin signalling 
is regulated by PARylation and tankyrase. Tankyrase is now an established core component of the 
Wnt/β-catenin network. Nonetheless, we are still far from fully understanding the complex roles 
tankyrase plays in the pathway. How does tankyrase promote Wnt/β-catenin signalling non-
catalytically, and do these mechanisms contribute to TNKSi resistance? Does scaffolding through 
tankyrase directly control β-catenin degradasome assembly, and how is this process regulated? How 
does AXIN PARylation promote the function of the Wnt signalosome? It will be interesting to 
explore the consequences of AXIN PARylation on both its conformation and interactions with 
components of both the signalosome and degradasome complexes. Given early indications of a role 
for tankyrase in APC-regulated destabilisation of AXIN, additional work is needed to decipher how 
APC limits AXIN abundance. Tankyrase inhibitors have now reached a remarkable specificity. The 
continued exploration of their pharmacodynamics, the identification of potential biomarkers for 
their therapeutic implementation and the in-depth analysis of emerging resistance and toxicity 
mechanisms are important avenues for future research. The latter will require a careful choice of 
model systems. The development of alternative tankyrase inhibition strategies through interfering 
with tankyrase’s non-catalytic scaffolding functions, in particular substrate binding, will 
undoubtedly offer new and exciting opportunities to understand tankyrase function and explore 
alternative therapeutic strategies. 
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Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2015/16 (Alexander et al., 2015a; 2015b). 
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Figure Legends 
 
Figure 1: Roles of tankyrase-dependent poly(ADP-ribosyl)ation in Wnt/β-catenin signalling. 
(A) Under basal Wnt/β-catenin signalling conditions, PARylation by tankyrase limits the levels of 
AXIN. Following PARylation, AXIN is ubiquitylated by RNF146 and targeted for proteasomal 
degradation. (B) Upon Wnt stimulation, PARylated AXIN is stabilised. PARylation facilitates 
AXIN interaction with LRP5/6 in Wnt signalosomes. Note that AXIN, Dishevelled and tankyrase 
polymerise and APC dimerises, and that this is a mechanistically important aspect of the dynamic 
signalling complexes (Fiedler et al., 2011; Kunttas-Tatli et al., 2014; Mariotti et al., 2016). For 
simplicity, proteins are shown as monomers; higher-order stoichiometry and multivalency are not 
reflected in the cartoons, and nomenclature does not consider multiple paralogues of pathway 
components. 
 
Figure 2: Scaffolding functions of tankyrase. 
(A) Domain organisation of human TNKS and TNKS2. HPS, N-terminal extension containing 
homopolymeric stretches of His, Pro and Ser; ARCs, ankyrin repeat clusters; SAM, sterile alpha 
motif domain; PARP, catalytic domain. The percentage identity of amino acids between TNKS and 
TNKS2 is specified for the indicated functional domains. (B) Domain organisation of AXIN1. 
TBM, tankyrase-binding motif; RGS, regulator of G-protein signalling domain; DAX, polymerising 
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domain present in Dishevelled and AXIN. Binding sites for other b-catenin destruction complex 
components are indicated. (C) Multiple sequence alignment of AXIN orthologues/paralogues from 
the indicated species, coloured by percentage identity. The TBMs are indicated. Note that 
Drosophila Axin lacks the second TBM. The red asterisk denotes a V26D mutation identified in 
murine Axin2 (Qian et al., 2011). (D) Structural (surface and cartoon) representation of murine 
Tnks ARC2-3, bound to the murine Axin1 N-terminus with two TBMs, shown in stick 
representation (PDB code 3UTM) (Morrone et al., 2012). In the crystal, ARC2-3 forms a dimer in 
which both copies of ARC2 are bound by one of the two TBMs of Axin1, respectively. (E) Detailed 
structural representation of the Axin1 TBMs (with indicated amino acid positions) on Tnks ARC2. 
The figure was generated by superimposing both ARC2-3 copies onto each other and displaying 
ARC2 bound to TBM1. Despite the N-terminal insertion in TBM2, the arginine (typically at 
position 1) occupies the same sub-pocket on the ARC, resulting in a looping out of the intervening 
residues. (F) Structural (transparent surface and cartoon) representation of a TNKS SAM polymer 
observed by X-ray crystallography (PDB code 5JU5) (Mariotti et al., 2016). (G) Avidity model for 
the interaction of AXIN and tankyrase, modified from Mariotti et al., 2016. Multivalency and 
polymerisation of both tankyrase and AXIN enable avidity contributions in the interaction between 
both proteins. Note that tankyrase polymerisation also promotes its PARP activity (Mariotti et al., 
2016; Riccio et al., 2016). 
 
Figure 3: b-catenin degradasomes induced by tankyrase inhibitors. 
SW480 CRC cells were treated with the tankyrase inhibitor XAV939 and immunostained for 
AXIN2 (red) and transiently expressed epitope-tagged wild-type TNKS2 (TNKS2 WT) or a 
TNKS2 mutant variant deficient in substrate binding (through site-directed mutation of ARCs 1, 2, 
4 and 5) and polymerisation (TNKS2 xx3xx VY903/920WA) (green). Yellow arrowheads indicate 
colocalisation of TNKS2 and AXIN2 in β-catenin degradasomes; red arrowheads indicate absence 
of colocalisation for the scaffolding-defective mutant variant of TNKS2. The figure was modified 
from Mariotti et al., 2016. 
 
Figure 4: Allosteric regulation of RNF146/Iduna by PAR binding. 
(A) Structure of a linear PAR chain, here attached to Asp/Glu. The O-glycosidic bonds linking 
ADP-ribose units are highlighted. The green box indicates iso-ADP-ribose. Tankyrase is thought to 
generate linear PAR chains (Rippmann et al., 2002); PAR branches are therefore omitted. (B) 
Domain organisation of human RNF146. Potential tankyrase-binding motifs (TBMs) are indicated 
(DaRosa et al., 2015). The boxed area, which includes the isolated RING domain, corresponds to 
(C). (C) Structural representation of RNF146 bound to iso-ADP-ribose (PDB code 4QPL) and the 
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E2 enzyme UbcH5a (DaRosa et al., 2015). The isolated RING domain of RNF146 (PDB code 
2D8T, one representative of the solution structure ensemble) is superimposed (DaRosa et al., 2015). 
Domains and corresponding Zn2+ ions are colour-coded as in (B). Key residues involved in PAR 
coordination and the allosteric switch are shown in stick representation. Note the clash occurring 
between the RING domain (yellow) and the E2 enzyme (blue) in the absence of the PAR ligand, 
and the conformational change upon PAR binding, resulting in a reorientation of Trp65. 
 
Figure 5: Binding modes of catalytic tankyrase inhibitors and alternative inhibition strategy. 
(A) Structural representation of TNKS/TNKS2 PARP domain:inhibitor complexes. Residues of the 
catalytic H-Y-E triad are indicated. Adenosine and nicotinamide sites are highlighted with blue and 
orange dashed circles, respectively, in the left and central panels, respectively. Left, structure of the 
TNKS2 PARP domain with the adenosine site binder G007-LK (shown in blue) (PDB code 4HYF) 
(Voronkov et al., 2013). Loops lining the inhibitor binding site are indicated. Centre, structure of 
the TNKS PARP domain with the nicotinamide site binder XAV939 (shown in orange) (PDB code 
3UH4) (Kirby et al., 2012). Right, structure of the TNKS PARP domain with a dual site binder 
(shown in green) (PDB code 4I9I) (Bregman et al., 2013b). The donor and acceptor sites are 
highlighted in magenta. (B) Structural representation of TNKS2 ARC4 (in surface representation) 
bound to two macrocyclised TBM peptides (PDB codes 5BXO and 5BXU) (Xu et al., 2017b). The 
peptide sequence is shown on the right with the position of the two different peptide staples, whose 
structures are shown. Amino acid positions of the TBM are indicated. 
 
Figure 6: Potential determinants of tankyrase inhibitor responses: APC mutation status and 
telomeric roles of tankyrase. 
(A) Schematic representation of APC with domains and motifs drawn to scale (reviewed by Stamos 
and Weis, 2013). 15- and 20-amino-acid-repeats (15R and 20R) bind β-catenin (except for 20R2), 
with the affinity of the 20Rs for β-catenin being enhanced by their phosphorylation (Eklof Spink et 
al., 2001; Ha et al., 2004; Xing et al., 2004). SAMP repeats bind to AXIN1/2 (Spink et al., 2000). 
20R2 and the catenin interaction domain (CID) / region B are required for b-catenin ubiquitylation 
but do not bind b-catenin; instead, CID / region B regulate AXIN1/2 binding to APC and are 
proposed to bind a-catenin (Liu et al., 2006; Kohler et al., 2008; Choi et al., 2013; Pronobis et al., 
2015). The mutation cluster region (MCR), a mutation hotspot in CRC (Kohler et al., 2008), is 
indicated in magenta. APC truncations observed in commonly used CRC cell lines are indicated by 
the arrows (Rowan et al., 2000; Ikediobi et al., 2006); labels are colour-coded according to the 
indicated effects of tankyrase inhibitors on AXIN and non-phospho (active) b-catenin levels and b-
catenin-dependent transcription. *Note that the classification of DLD-1 and HCT-15 cells as 
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TNKSi-sensitive or -resistant varies between studies, given an ‘intermediate’ response (Huang et 
al., 2009; Lau et al., 2013; de la Roche et al., 2014; Tanaka et al., 2017). Very low AXIN1/2 levels 
in KM12 cells (Tanaka et al., 2017) may be responsible for non-detectable AXIN accumulation 
upon tankyrase inhibition. (B) Multiple sequence alignment of the N-termini of TERF1/TRF1 
(telomeric repeat binding factor 1) orthologues from the indicated species, coloured by percentage 
identity. The amino acid numbering refers to human TERF1. The 8-amino-acid TBM is boxed in 
red. The murine Terf1 orthologue sequence is boxed in yellow and shows no conservation of the 
TBM.  
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Table 1: Tankyrase inhibitors. 
The structures and properties of reported tankyrase-selective inhibitors are shown, grouped 
according to binding site. Dual site binders occupy both the nicotinamide and adenosine subsites. 
One example structure is given if numerous similar compounds in a series were detailed in the 
literature. Biochemical IC50 values (i.e., corresponding to inhibition of PARP activity) for TNKS, 
TNKS2, PARP1 and PARP2 and IC50 values in Wnt/b-catenin reporter assays are listed if reported. 
“-“ indicates that values have not been reported. Note that NVP-TNKS656 is reported as a “triple 
site binder”, also interacting with a hydrophobic ‘nook’ adjacent to the phosphate-binding groove 
(Shultz et al., 2012; 2013). *Although the IC50 for PARP1/2 was not determined for compound 9 
(Elliott et al., 2015), other compounds in the same series displayed IC50 values for PARP1/2 of at 
least one order of magnitude above those for TNKS (Elliott et al., 2015; Paine et al., 2015). 
No. Tankyrase Inhibitor 
TNKS 
IC50 
(nM) 
TNKS2 
IC50 (nM) 
PARP1 
[PARP2] 
IC50 (nM) 
IC50 in 
Wnt 
reporter 
assay 
(nM) 
Binding Site References 
1 
 
 
 
 
XAV939 
11 4 
PARP 
domain: 
2194 
[114] 
 
full-
length: 
74 
[27] 
78 
(HEK293
, Wnt-3a) 
Nicotinamide 
(Huang et al., 
2009; Karlberg 
et al., 2010; 
Kirby et al., 
2012; Shultz 
et al., 2012; 
Thorsell et al., 
2017) 
2 
 
 
 
 
 
Flavone-based 
6 72 19,100 [34,900] - Nicotinamide 
(Narwal et al., 
2013a; 2013b) 
 
3 
 
Quinolinyl-phenyl-based 
860 52 >10,000 [>10,000] - Nicotinamide 
(Larsson et al., 
2013) 
4 
 
     Quinolinyl-benzamide  
- 9 - - Nicotinamide 
(Larsson et al., 
2013) 
5 
 
 
 
 
 
2-arylquinazolin-4-one 
32 9 >5,000 - Nicotinamide 
(Nathubhai et 
al., 2013; 
2016) 
NH
O
Me
F
S N
N
HO
CF3
O
O
NH
O
Me
Cl
HN
O
O
N
NH
Me
O
Br
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6 
Triazolo piridazine  
12 200 >10,000 [>10,000] - Nicotinamide 
(Liscio et al., 
2014) 
7 
 
Tetrahydro-1,6-naphthyridinone 
1.7 1.1 3,400 - Nicotinamide 
(Kumpan et 
al., 2015) 
8 
 
 
 
 
 
Tetrahydroquinazolinone-based 
370 71 5,900 [4,200] - Nicotinamide 
(Nkizinkiko et 
al., 2015) 
9 
 
Isoquinolin-1-one 
12 - - * 25 (DLD-1) Nicotinamide 
(Elliott et al., 
2015; Paine et 
al., 2015) 
10 
Tetrazoloquinoxaline 
32 - >1,995 
32 
(HEK293
, Wnt-3a) 
Nicotinamide 
 
(Thomson et 
al., 2017) 
11 
 
G-631 
8 24 >10,000 
8 
(HEK293
, Wnt-3a) 
Nicotinamide 
(patent by 
Feng et al., 
2013; Zhong 
et al., 2016b) 
12 
 
 
 
 
IWR-1 
131 56 >18,750 [>18,750] 
180 
(L cells, 
Wnt-3a) 
Adenosine 
(Chen et al., 
2009; Lu et al., 
2009; Huang 
et al., 2009; 
Gunaydin et 
al., 2012) 
13 
 
 
 
 
 
 
JW67 
- - - 
1,170 
(HEK293
, Wnt-3a) 
Unknown 
(Waaler et al., 
2011) 
14 
JW74 
2,550 650 - 
790 
(HEK293
, Wnt-3a) 
Adenosine 
(Waaler et al., 
2011; Shultz 
et al., 2012; 
Voronkov et 
al., 2013) 
15 
[1,2,4]Triazole, based on JW74 
- 33 >19,000 [>19,000] 
215 
(HEK293
, Wnt-3a) 
Adenosine 
(Shultz et al., 
2012) 
N
NH
Me
O
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16 
WIKI4 
26 15 >10,000 [>10,000] - Adenosine 
(James et al., 
2012; 
Haikarainen et 
al., 2013) 
17 
JW55 
1,800 2,010 - 
1,230 
(HEK293
, Wnt-3a) 
Adenosine 
(Waaler et al., 
2012; 
Haikarainen et 
al., 2016) 
18 
 
G007-LK  
46 25 >10,000 [>10,000] 
50 
(HEK293
, Wnt-3a) 
Adenosine 
(Lau et al., 
2013; 
Voronkov et 
al., 2013) 
 
19 
Oxazolidinone 
1 - 
>85,000 
[>170,000
] 
- Adenosine 
(Bregman et 
al., 2013a) 
20 
 
 
 
 
 
 
 
Oxazolidinone-based 
2 2 
>85,000 
[>170,000
] 
12 
(DLD-1) Adenosine 
(Huang et al., 
2013) 
21 
K-756 
31 36 - 110 (DLD-1) Adenosine 
(Okada-
Iwasaki et al., 
2016) 
22 
Long quinazolinone 
8 2 [931] 
36,000 
(HEK293
, Wnt-3a) 
Dual site 
(Bregman et 
al., 2013b) 
23 
Long quinazolinone-based 
0.2 2.5 - 1.3 (DLD-1) Dual site 
(Hua et al., 
2013) 
24 
 
Long quinazolinone-based 
5.1 0.1 6,500 [11,600] 
37 
(HEK293
, Wnt-3a) 
Dual site 
(Nathubhai et 
al., 2017) 
N
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25 
Pyrimidinone 
3 1 2.0 [0.5] 
5 
(DLD-1) Dual site 
(Johannes et 
al., 2015a) 
26 
 
NVP-TNKS656 
- 6 >19,000 [>30,000] 
3.5 
(HEK293
, Wnt-3a) 
Dual site 
(Shultz et al., 
2013) 
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